NASDAQ: GPCR - Structure Therapeutics Inc.

Rentabilidade por seis meses: -47.38%
Rendimento de dividendos: 0.00%
Setor: Healthcare

Cronograma de promoção Structure Therapeutics Inc.

Agenda avançada Gráfico simples
Financial Markets by TradingView

Sobre a empresa Structure Therapeutics Inc.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

mais detalhes
The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. The company was founded in 2016 and is headquartered in South San Francisco, California.
Adicionar à lista de comparação
Adicionar à lista de observação
Adicionar ao portfólio
Adicionar aviso de preço

IPO date 2023-02-03
ISIN US86366E1064
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://structuretx.com
Цена ао 20.4
Alteração de preço por dia: +3.19% (20.4)
Alteração de preço por semana: -6.94% (22.62)
Alteração de preço por mês: -13.48% (24.33)
Alteração de preço em 3 meses: -32.64% (31.25)
Mudança de preço em seis meses: -47.38% (40)
Mudança de preço por ano: -40.54% (35.4)
Mudança de preço desde o início do ano: -24.55% (27.9)
Todos os parâmetros

Subestimação

Nome Significado Nota
P/S 0 0
P/BV 2.88 6
P/E 0 0
EV/EBITDA -11.6 0
Total: 2.75

Eficiência

Nome Significado Nota
ROA, % -18.58 0
ROE, % -19.77 0
Total: 0

Dividendos

Nome Significado Nota
Div yield, % 0 0
DSI 0 0
Total: 0

Obrigação

Nome Significado Nota
Debt/EBITDA -0.0536 10
Total: 9.6

Impulso de crescimento

Nome Significado Nota
Rentabilidade Revenue, % 0 0
Rentabilidade Ebitda, % 640268.75 10
Rentabilidade EPS, % 31968.75 10
Total: 8
Mais detalhes

Instituições Volume Compartilhar, %
Wellington Management Group, LLP 4372326 9.38
FMR, LLC 4034584 8.66
Driehaus Capital Management, LLC 2599079 5.58
Avoro Capital Advisors LLC 2333333 5.01
Federated Hermes, Inc. 2267206 4.87
Tcg Crossover Management, Llc 2109584 4.53
Adage Capital Partners GP L.L.C. 1756918 3.77
Price (T.Rowe) Associates Inc 1679436 3.6
Janus Henderson Group PLC 1544416 3.31
T. Rowe Price Investment Management, Inc. 1312195 2.82

ETFCompartilhar, %Rentabilidade para o ano, %Dividendos, %
Future Tech ETF 0.24233 426.34 0.8416
Principal Healthcare Innovators ETF 0.24233 618.5 0.8416
0.24522.420.84



Supervisor Cargo Pagamento Ano de nascimento
Dr. Raymond C. Stevens Ph.D. CEO & Director 890.38k 1964 (61 ano)
Dr. Yingli Ma Ph.D. Chief Technology Officer 497.58k 1974 (51 ano)
Mr. Jun S. Yoon Co- Founder, CFO & Secretary 627.64k 1978 (47 anos)
Dr. Xichen Lin Ph.D. Chief Scientific Officer N/A 1974 (51 ano)
Mr. Tony Peng Senior Vice President of Legal N/A
Mr. Bob Gatmaitan Senior Vice President of People N/A
Dr. Hui Lei Ph.D. Senior Vice President of Chemistry N/A
Dr. Fang Zhang Ph.D. Executive VP & Head of Biology N/A
Ms. Lani Ibarra Senior Vice President of Clinical Development Operations N/A
Dr. Xinglong Jiang Ph.D. Senior Vice President of Preclinical Development

Endereço: United States, South San Francisco. CA, 611 Gateway Boulevard - abrir no Google Maps, abrir mapas Yandex
Site: https://structuretx.com